Physician
Hematology
Dr. Joseph Pidala, MD
|
|
Give Review
Joseph Pidala works in the field of Hematology. He studied medicine at University of South Florida College of Medicine. University of South Florida College of Medicine has a rank of 79 in research and a 85 in primary care Joseph Pidala is a published physician. He published 78 publications, including: 'Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.' Dr. Joseph Pidala is registered with Medicare.
Publications
- Late Acute and Chronic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation.
- Sirolimus, tacrolimus and antithymocyte globulin as GVHD prophylaxis in HLA-mismatched unrelated donor hematopoietic Cell transplantation: a single institution experie...
- Predictors of survival, non-relapse mortality and failure-free survival in patients treated for Chronic graft-versus-host disease.
- Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.
- Ofatumumab in combination with glucocorticoids for primary therapy of Chronic graft vs. host disease: Phase I trial results.
- Increasing incidence of Chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
- CD4+ T cell STAT3 phosphorylation precedes Acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.
- Sleep Disruption in Hematopoietic Cell Transplantation Recipients: Prevalence, Severity, and Clinical Management.
- Association of severity of organ involvement with mortality and recurrent malignancy in patients with Chronic graft-versus-host disease.
- Long-term Survival and Late Effects among 1-year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Synd...
- Non-permissive -DPB1 mismatch among otherwise HLA-matched donor-recipient pairs results in increased oVerall mortality after myeloablative unrelated allogeneic hematop...
- Caregivers' quality of life after blood and marrow transplantation: a qualitative study.
- Impact of Age on Quality of Life, Functional Status and Survival in Patients with Chronic Graft-versus-Host Disease.
- Assessment of joint and fascia manifestations in Chronic graft-versus-host disease.
- Allotransplantation for patients age 40 years and greater with non-Hodgkin Lymphoma (NHL): encouraging progression-free survival.
- Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in Chronic gr...
- STAT5 polarization promotes iTregs and suppresses human T-Cell alloresponses while preserving CTL capacity.
- Clinical guide to fertility preservation in hematopoietic Cell transplant recipients.
- Conditioning Chemotherapy Dose Adjustment in Obese Patients: A Review and Position Statement by the American Society for Blood and Marrow Transplantation Practice Guid...
- Investigator feedback about the 2005 NIH diagnostic and scoring criteria for Chronic GVHD.
- Patient education in allogeneic hematopoietic Cell transplant: what patients wish they had known about quality of life.
- Pharmacokinetically-targeted BU and fludarabine as conditioning before allogeneic hematopoietic Cell transplantation for adults with ALL in first remission.
- Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhi...
- Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe Acute GVHD and mortality.
- Human regulatory T cells against minor histocompatibility antigens: ex vivo expansion for prevention of Graft-versus-host disease.
- Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic Syndromes: an international co...
- Biologic markers of Chronic GVHD.
- The impact of HLA unidirectional mismatches on the outcome of myeloablative hematopoietic stem Cell transplantation with unrelated donors.
- Analysis of Gastrointestinal and Hepatic Chronic Grant-versus-Host Disease Manifestations on Major Outcomes: A Chronic Grant-versus-Host Disease Consortium Study.
- Comorbidity burden in patients with Chronic GVHD.
- A systematic review and meta-analysis of changes in cognitive functioning in adults undergoing hematopoietic Cell transplantation.
- Phase II study of CD4+guided pentostatin lymphodepletion and pharmacokinetically-targeted busulfan as conditioning for hematopoietic cell alloGrafting.
- Allogeneic hematopoietic Cell transplantation for consolidation of VGPR or CR for newly diagnosed multiple myeloma.
- Hand Grip Strength and 2-Minute Walk Test in Chronic Graft-versus-Host Disease Assessment: Analysis from the Chronic GVHD Consortium.
- Physician perceptions and practice patterns regarding fertility preservation in hematopoietic Cell transplant recipients.
- Measurement of oral Chronic GVHD: results from the Chronic GVHD Consortium.
- Practice variation in physician referral for allogeneic hematopoietic Cell transplantation.
- A randomized phase II study to evaluate tacrolimus in combination with sirolimus or methotrexate after allogeneic hematopoietic Cell transplantation.
- Race/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization.
- Clinical predictors of cognitive function in adults treated with hematopoietic Cell transplantation.
- Bortezomib salvage followed by a Phase I/II study of bortezomib plus high-dose melphalan and tandem autologous transplantation for patients with primary resistant myel...
- Tolerance Associated Gene Expression following Allogeneic Hematopoietic Cell Transplantation.
- Mycophenolate mofetil for the management of steroid-refractory Acute graft vs host disease.
- Sirolimus for treatment of steroid-refractory Acute graft-versus-host disease.
- Targeted i.v. BU and fludarabine (t-i.v. BU/Flu) provides effective control of AML in adults with reduced toxicity.
- Pulmonary alveolar proteinosis following allogeneic hematopoietic Cell transplantation.
- Increased N-acetyl-beta-glucosaminidase activity in primary Breast carcinomas corresponds to a decrease in N-acetylglucosamine containing proteins.
- Graft-vs-host disease following allogeneic hematopoietic cell transplantation.
- Progress in hematopoietic Cell transplantation.
- Allogeneic hematopoietic cell transplantation for adult Acute lymphoblastic leukemia (ALL) in first complete remission.
- Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly.
- Have we improved in preventing and treating Acute graft-versus-host disease?
- The global severity of Chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-r...
- Global and organ-specific Chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.
- Sensitivity of changes in Chronic graft-versus-host disease activity to changes in patient-reported quality of life: results from the Chronic Graft-versus-Host Disease...
- Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal Acute myeloid leukemia (CN-AML) and FLT3ITD.
- Sirolimus demonstrates activity in the primary therapy of Acute graft-versus-host disease without systemic glucocorticoids.
- Variation in management of Immune suppression after allogeneic hematopoietic cell transplantation.
- Fludarabine and pharmacokinetic-targeted busulfan before allografting for adults with Acute lymphoid leukemia.
- Patient-reported quality of life is associated with severity of Chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic...
- Targeted IV busulfan and fludarabine followed by post-allogeneic hematopoietic Cell transplantation rituximab demonstrate encouraging activity in CD20+ lymphoid malign...
- ATG prevents severe Acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation.
- Pentostatin as rescue therapy for glucocorticoid-refractory Acute and chronic graft-versus-host disease.
- Pharmacokinetic targeting of intravenous busulfan reduces conditioning regimen related toxicity following allogeneic hematopoietic cell transplantation for Acute myelo...
- Allogeneic hematopoietic Cell transplantation for myelofibrosis: a 10-year experience at single institution.
- Dysglycemia following glucocorticoid therapy for Acute graft-versus-host disease adversely affects transplantation outcomes.
- Thrombotic microangiopathy after GVHD prophylaxis with tacrolimus/sirolimus: a call for use of consensus definition in reporting.
- Glucocorticoid-refractory Acute graft-versus-host disease.
- Can antigen-specific regulatory T cells protect against Graft versus host disease and spare anti-malignancy alloresponse?
- Biomarkers to discern transplantation tolerance after allogeneic hematopoietic Cell transplantation.
- Health-related quality of life following haematopoietic Cell transplantation: patient education, evaluation and intervention.
- Decision analysis of peripheral blood versus bone marrow hematopoietic stem Cells for allogeneic hematopoietic Cell transplantation.
- Infliximab for managing steroid-refractory Acute graft-versus-host disease.
- Sirolimus as primary treatment of Acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
- Quality of life after allogeneic hematopoietic Cell transplantation.
- A case of Acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13).
- Essential fatty acids and phenolic acids from extracts and leachates of southern cattail (Typha domingensis P.).
Procedures Preformed
- HPC Transplantation (Stem Cell Transplant)
Conditions Treated
- Acute Leukemia
- Anemia
- Antiphospholipid Syndrome (APS)
- Breast Cancer
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Amerigroup (Wellpoint)
- AvMed
- Blue Card PPO
- Blue Care HMO
- BlueDental Choice
- NetworkBlue
- Cigna
- Commercial Insurance Company
- CoreSource
- Wellpath Preferred PPO
- Employer Group Open Access HMO
- Employer Group PPO
- Fallon Community Health Plan
- Federal Employee Program (FEP)
- First Health (Coventry Health Care) PPO
- Medicare Advantage PFFS
- Choice Care PPO
- Preferred PPO
- Select HMO
- Tampa Bay CoreNet
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Choice Plus POS
- Neighborhood Health Partnership
- Options PPO
- United Healthcare
Education
-
University of South Florida -
Beth Israel Deaconess Medical Center -
University of South Florida College of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1104025592 | |
| NPPES Provider LastName | PIDALA | |
| NPPES Provider FirstName | JOSEPH | |
| NPPES Provider ZIPCode | 336063508 | |
| NPPES Provider State | FL | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 155.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 13.0 | |
| Percent Opioid Claims | 8.39 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1104025592 |
| Last Name Of The Provider | PIDALA |
| First Name Of The Provider | JOSEPH |
| View All |
Similar Doctors
|
Dr. Jinming Song, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Ron D. Schiff, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Larry Kvols, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph G. Sinkovics, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Salvador Bruno, MD |
|
Dr. Magda E. Melchert, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kenneth Zuckerman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Julia A. Cogburn, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Alberto A. Chiappori, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen G. Patterson, MD |
|
|
Dr. Karen K. Fields, MD |
|
|
Dr. Loveleen Kang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Asmita Mishra, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Bennett W. Yu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Estrella M. Carballido, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Darrin Beaupre, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard D. Hall Jr., MD |
|
|
Dr. Janet M. McNaughton, MD
This Doctor is OpenDoctor Recommended.
|